The BCGΔBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo.

[1]  John L. Johnson,et al.  Bacillus Calmette–Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses , 2016, The Journal of Immunology.

[2]  Deepak L. Bhatt,et al.  Thiol reductive stress induces cellulose-anchored biofilm formation in Mycobacterium tuberculosis , 2016, Nature Communications.

[3]  M. Flores-Valdez.  Vaccines Directed Against Microorganisms or Their Products Present During Biofilm Lifestyle: Can We Make a Translation as a Broad Biological Model to Tuberculosis? , 2016, Front. Microbiol..

[4]  Tareq B. Malas,et al.  Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations , 2015, Scientific Reports.

[5]  H. Steinberg,et al.  Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain. , 2015, Vaccine.

[6]  J. Turner,et al.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? , 2015, Vaccine.

[7]  S. Porcelli,et al.  Current efforts and future prospects in the development of live mycobacteria as vaccines , 2015, Expert review of vaccines.

[8]  D. Hokey,et al.  Tuberculosis vaccine development: Shifting focus amid increasing development challenges , 2015, Human vaccines & immunotherapeutics.

[9]  M. Sánchez.  Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia , 2015, Front. Microbiol..

[10]  C. Espitia,et al.  A PE_PGRS33 protein of Mycobacterium tuberculosis: an ideal target for future tuberculosis vaccine design , 2015, Expert review of vaccines.

[11]  C. Waters,et al.  The cyclic di‐GMP phosphodiesterase gene Rv1357c/BCG1419c affects BCG Pellicle production and In Vivo maintenance , 2015, IUBMB life.

[12]  M. Netea,et al.  BCG-induced protection: effects on innate immune memory. , 2014, Seminars in immunology.

[13]  B. Gicquel,et al.  Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. , 2013, Vaccine.

[14]  Zhi-jie Liu,et al.  Binding of bacterial secondary messenger molecule c di-GMP is a STING operation , 2012, Protein & Cell.

[15]  N. Franco,et al.  Animal Welfare in Studies on Murine Tuberculosis: Assessing Progress over a 12-Year Period and the Need for Further Improvement , 2012, PloS one.

[16]  N. Franco,et al.  How “Humane” Is Your Endpoint?—Refining the Science-Driven Approach for Termination of Animal Studies of Chronic Infection , 2012, PLoS pathogens.

[17]  J. Flynn,et al.  Macrophages and control of granulomatous inflammation in tuberculosis , 2011, Mucosal Immunology.

[18]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[19]  Chen Tian,et al.  Roles of PE_PGRS family in Mycobacterium tuberculosis pathogenesis and novel measures against tuberculosis. , 2010, Microbial pathogenesis.

[20]  I. Smith,et al.  Immunogenicity and Protection Induced by a Mycobacterium tuberculosissigE Mutant in a BALB/c Mouse Model of Progressive Pulmonary Tuberculosis , 2010, Infection and Immunity.

[21]  Wangxue Chen,et al.  The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. , 2010, Vaccine.

[22]  J. C. Sundaramurthi,et al.  Immunological and proteomic analysis of preparative isoelectric focusing separated culture filtrate antigens of Mycobacterium tuberculosis. , 2010, Experimental and molecular pathology.

[23]  S. Kaufmann,et al.  Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. , 2009, Vaccine.

[24]  S. Kaufmann,et al.  Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection , 2009, PloS one.

[25]  G. Besra,et al.  Mycolic Acid Modification by the mmaA4 Gene of M. tuberculosis Modulates IL-12 Production , 2008, PLoS pathogens.

[26]  A. Camilli,et al.  Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. , 2007, Annual review of microbiology.

[27]  R. Hernández-Pando,et al.  The PGRS domain of Mycobacterium tuberculosis PE_PGRS Rv1759c antigen is an efficient subunit vaccine to prevent reactivation in a murine model of chronic tuberculosis. , 2007, Vaccine.

[28]  R. Hernández-Pando,et al.  Mycobacterium bovis BCG Substrains Confer Different Levels of Protection against Mycobacterium tuberculosis Infection in a BALB/c Model of Progressive Pulmonary Tuberculosis , 2006, Infection and Immunity.

[29]  Ying Zhang,et al.  Persistent and dormant tubercle bacilli and latent tuberculosis. , 2004, Frontiers in bioscience : a journal and virtual library.

[30]  G. Rook,et al.  Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis , 2002, Clinical and experimental immunology.

[31]  C. Volker,et al.  Purification and Biochemical Characterization of theMycobacterium tuberculosis β-Ketoacyl-acyl Carrier Protein Synthases KasA and KasB* , 2001, The Journal of Biological Chemistry.

[32]  P. Brennan,et al.  Expression, purification, and characterization of the Mycobacterium tuberculosis acyl carrier protein, AcpM. , 2001, Biochimica et biophysica acta.

[33]  P. Andersen,et al.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.

[34]  John Chan,et al.  Depletion of Cd4+ T Cells Causes Reactivation of Murine Persistent Tuberculosis despite Continued Expression of Interferon γ and Nitric Oxide Synthase 2 , 2000, The Journal of experimental medicine.

[35]  J. Ivanyi,et al.  Mechanisms of recrudescence of Mycobacterium bovis BCG infection in mice , 1989, Infection and immunity.

[36]  J. Flynn,et al.  The immunological aspects of latency in tuberculosis. , 2004, Clinical immunology.